Nicolás Triantafilo C. (@nico30f) header
Nicolás Triantafilo C. (@nico30f) profile picture

Hematólogo. Linfomas y Leucemia Linfocítica Crónica. #LEx

Joined August 2018
Photo by Nicolás Triantafilo C. (@nico30f)Photo by Nicolás Triantafilo C. (@nico30f)Photo by Nicolás Triantafilo C. (@nico30f)Photo by Nicolás Triantafilo C. (@nico30f)Photo by Nicolás Triantafilo C. (@nico30f)Photo by Nicolás Triantafilo C. (@nico30f)Photo by Nicolás Triantafilo C. (@nico30f)Photo by Nicolás Triantafilo C. (@nico30f)Photo by Nicolás Triantafilo C. (@nico30f)Photo by Nicolás Triantafilo C. (@nico30f)
Nicolás Triantafilo C. retweeted
Bridging RT, but make it definitive. CABI: ablative RT to every PET-avid site before axi-cel, mostly bulky. Love the idea. Single center, early follow-up, frequent ICANS. #ASH26 #lymsm #CARTcells onlineprogram.hematology.org…
1
3
9
635
Nicolás Triantafilo C. retweeted
Does CD5+ LBCL present unique questions for CNS prophylaxis? Reply in @JCO_ASCO with @mattwilson2287 & @Dr_KatLewis #lymsm Reply to: Unanswered Question Regarding CNS Prophylaxis in CD5-Positive Diffuse Large B-Cell Lymphoma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…
18
1
46
3,559
Nicolás Triantafilo C. retweeted
Sepsis complicated 6.2% of CAR-T hospitalizations in the US (2017-2022) and changed everything: in-hospital mortality 28.7% vs 1.1% (aOR 33.96), plus more organ failure and thrombohemorrhagic events. Infection prevention is not optional. #mmsm doi.org/10.1016/j.jtct.2026.…
3
7
511
Nicolás Triantafilo C. retweeted
LTB-TREAT: A validated international prognostic model for time to treatment in low tumour burden follicular lymphoma buff.ly/nJ1dh3x
1
4
4
704
Nicolás Triantafilo C. retweeted
Changes in muscle and fat distribution occur early in treatment highlighting the need for interventions to stabilize body composition. Patients with a higher volume of disease are more likely to experience certain side effects such as nerve pain. ow.ly/JWeb5104eB5
1
4
13
1,720
Nicolás Triantafilo C. retweeted
CAR-NK cells engineered to express IL-15 produced responses in 8 of 11 patients with refractory lymphoma or leukemia, including 7 complete responses. No cytokine release syndrome, neurotoxicity or graft-versus-host disease was observed. doi.org/10.1056/NEJMoa191060… this is why I love $IBRX and #anktiva
4
15
1
101
4,752
Nicolás Triantafilo C. retweeted
CMV reactivation is common after CAR T-cell therapy for #LBCL, including in the 2L setting. Corticosteroid exposure is a major risk factor for CMV reactivation. Read in Blood ICT: ow.ly/tT205103NCK
13
2
37
3,524
Nicolás Triantafilo C. retweeted
New publication 📝 Results from a phase II trial, published in @BloodPortfolio, show that glofitamab + pola-R-CHP achieved a 95% CR rate in patients with newly diagnosed DLBCL or HGBCL. Learn more about aggressive B-cell lymphomas: bit.ly/4aCi7Xu #DLBCL #Lymphoma #lymsm #MedNews #MedEd
1
4
6
662
Nicolás Triantafilo C. retweeted
Excited to share our new @BloodPortfolio manuscript comparing CAR-T vs BsAb in R/R FL. In addition to comparing survival, we also studied "time toxicity," or how much time patients spend physically interacting with the healthcare system. #lymsm 🧵 ashpublications.org/bloodadv…
3
19
3
73
5,056
Nicolás Triantafilo C. retweeted
Just published in @BloodAdvances! "CAR T-cell therapy referral patterns and utilization for relapsed/refractory large B-cell lymphoma in the United States" Only ~15% of patients receive CAR T. We need to continue generating data, raising awareness, and improving access and utilization. ashpublications.org/bloodadv… Thanks to all the authors and collaborators at @bmsnews @lymphomaphilia @KrishPatelMD @LNastoupilMD @mana1981
1
12
28
1,801